leisure time -WSS

leisure time

author：focus 2025-08-12 09:13:07 - browse：54

Element Biosciences exterior -- biotech coverage from STAT — Element Biosciences exterior Element Biosciences

SAN DIEGO — Companies racing to read the genome accurately, quickly, and affordably have hit a snag recently, with several firms reporting that their growth has slowed, stalled, or reversed. Upstart Element Biosciences is hoping it can succeed despite the challenging market conditions.

The San Diego firm launched a $290,000 sequencer, dubbed Aviti, in March 2022 and now has 150 instruments installed in more than 25 countries, according to a sales update Element shared with STAT. The modest growth comes at a time when some other players are struggling. Singular Genomics announced layoffs of 20% of its workforce earlier this year after the lackluster launch of its own sequencer. And Pacific Biosciences recently laid off nearly 200 employees after reporting disappointing first-quarter sales.

Element still has a long way to go in its bid to rival Illumina, a genomics giant that dominates 80% of the sequencing market and has more than 23,000 instruments in use around the world. That includes the NextSeq 2000, a $335,000 sequencer with a similar output to Aviti. Element is betting its blend of accuracy and a more moderate price point can help it carve out a niche of academic and biopharma customers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Teladoc has a new CEO, but challenges remain the same

WSS

The EPA's new lead rule: How one expert crunched the numbers

Pharma companies must ensure equitable access to obesity drugs

Medical device trials still don't enroll enough women, study finds

What don’t we know about an Alzheimer’s drug side effect?

My daughter's legacy lives on through her writing, phage therapy

Moderna says combo Covid

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

'Essentially witchcraft:' A former naturopath takes on the field

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Mayo Clinic plans $5B tech

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

'Essentially witchcraft:' A former naturopath takes on the field

What does generative AI mean for health care? We asked experts

How to pay for weight loss drugs and save Medicare

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Organ aging and disease risk measured by new blood test

entertainment

Takeda, Janssen join wearable maker to measure scratching

Deposition: Sackler embraced plan to conceal OxyContin’s strength

ReNAgade cuts staff seven months after raising $300 million

'Essentially witchcraft:' A former naturopath takes on the field

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

'Essentially witchcraft:' A former naturopath takes on the field

hotspot

leisure time

hotspot

hotspot